These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 34453865)

  • 1. Epigenetic code during mycobacterial infections: therapeutic implications for tuberculosis.
    Fatima S; Kumari A; Agarwal M; Pahuja I; Yadav V; Dwivedi VP; Bhaskar A
    FEBS J; 2022 Jul; 289(14):4172-4191. PubMed ID: 34453865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Frontier of mycobacterium research--host vs. mycobacterium].
    Okada M; Shirakawa T
    Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of epigenetics, bacterial and host factors in progression of Mycobacterium tuberculosis infection.
    Marimani M; Ahmad A; Duse A
    Tuberculosis (Edinb); 2018 Dec; 113():200-214. PubMed ID: 30514504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Repurposing Tamoxifen as Potential Host-Directed Therapeutic for Tuberculosis.
    Boland R; Heemskerk MT; Forn-Cuní G; Korbee CJ; Walburg KV; Esselink JJ; Carvalho Dos Santos C; de Waal AM; van der Hoeven DCM; van der Sar E; de Ries AS; Xie J; Spaink HP; van der Vaart M; Haks MC; Meijer AH; Ottenhoff THM
    mBio; 2023 Feb; 14(1):e0302422. PubMed ID: 36475748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
    Tomioka H
    Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Host-Pathogen Interaction as a Novel Target for Host-Directed Therapies in Tuberculosis.
    Abreu R; Giri P; Quinn F
    Front Immunol; 2020; 11():1553. PubMed ID: 32849525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Recent progress in mycobacteriology].
    Okada M; Kobayashi K
    Kekkaku; 2007 Oct; 82(10):783-99. PubMed ID: 18018602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Host-directed therapy targeting the Mycobacterium tuberculosis granuloma: a review.
    Kiran D; Podell BK; Chambers M; Basaraba RJ
    Semin Immunopathol; 2016 Mar; 38(2):167-83. PubMed ID: 26510950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prospects for development of new antituberculous drugs].
    Tomioka H
    Kekkaku; 2002 Aug; 77(8):573-84. PubMed ID: 12235850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Harnessing Biological Insight to Accelerate Tuberculosis Drug Discovery.
    de Wet TJ; Warner DF; Mizrahi V
    Acc Chem Res; 2019 Aug; 52(8):2340-2348. PubMed ID: 31361123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetics-directed drug discovery for combating Mycobacterium tuberculosis infection.
    Quan Y; Xiong L; Chen J; Zhang HY
    J Biomol Struct Dyn; 2017 Feb; 35(3):616-621. PubMed ID: 26900080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autophagy Induction as a Host-Directed Therapeutic Strategy against
    Adikesavalu H; Gopalaswamy R; Kumar A; Ranganathan UD; Shanmugam S
    Medicina (Kaunas); 2021 May; 57(6):. PubMed ID: 34070995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Host Directed Therapies for Tuberculosis: Futures Strategies for an Ancient Disease.
    Palucci I; Delogu G
    Chemotherapy; 2018; 63(3):172-180. PubMed ID: 30032143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Repurposing Immunomodulatory Drugs to Combat Tuberculosis.
    Fatima S; Bhaskar A; Dwivedi VP
    Front Immunol; 2021; 12():645485. PubMed ID: 33927718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can We Exploit Inflammasomes for Host-Directed Therapy in the Fight against
    Cebani L; Mvubu NE
    Int J Mol Sci; 2024 Jul; 25(15):. PubMed ID: 39125766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Host sirtuin 2 as an immunotherapeutic target against tuberculosis.
    Bhaskar A; Kumar S; Khan MZ; Singh A; Dwivedi VP; Nandicoori VK
    Elife; 2020 Jul; 9():. PubMed ID: 32697192
    [No Abstract]   [Full Text] [Related]  

  • 18. Alterations in molecular response of Mycobacterium tuberculosis against anti-tuberculosis drugs.
    Bhattacharjee A; Sarma S; Sen T; Singh AK
    Mol Biol Rep; 2022 May; 49(5):3987-4002. PubMed ID: 35066765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Small Molecule Mediated Restoration of Mitochondrial Function Augments Anti-Mycobacterial Activity of Human Macrophages Subjected to Cholesterol Induced Asymptomatic Dyslipidemia.
    Asalla S; Mohareer K; Banerjee S
    Front Cell Infect Microbiol; 2017; 7():439. PubMed ID: 29067283
    [No Abstract]   [Full Text] [Related]  

  • 20. Host factors subverted by
    Kalra R; Tiwari D; Dkhar HK; Bhagyaraj E; Kumar R; Bhardwaj A; Gupta P
    Int Rev Immunol; 2023; 42(1):43-70. PubMed ID: 34678117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.